FDA Approves Durvalumab for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

On November 25, the FDA approved durvalumab with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma.

For more information, read the FDA announcement and the AstraZeneca press release.

Posted on 11/25/2025